Aurobindo Pharma Ltd
Aurobindo Pharma Ltd is a Public Non-govt company company incorporated in 1986 and based in Telangana, India. Aurobindo Pharma Ltd operates in Hina powder, manufacturing (NIC 24239) with authorized capital of ₹261.15 Cr and paid-up capital of ₹58.59 Cr. For 2020-21, the company reported revenue of ₹15823.68 Cr and profit after tax of ₹3112.91 Cr. RegisterKaro's Compliance Health Score for the company is 35/100 (grade F), reflecting a weak compliance posture.
Tergene Biotech - Vaccines against bacterial infections.. Acquired by Aurobindo Pharma. Raised funding over 2 rounds from 2 investors.
Quick facts
Directors
LockedDirectors, DINs & appointment history for Aurobindo Pharma Ltd.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
MCA Filings
Locked| Form | FY | Filed | Due | Delay | Status |
|---|---|---|---|---|---|
| AOC-4 | FY2024-25 | 30 Oct 2024 | 30 Oct 2024 | 0d | filed |
| MGT-7 | FY2024-25 | 26 Nov 2024 | 29 Nov 2024 | 0d | filed |
| AOC-4 | FY2023-24 | 30 Oct 2023 | 30 Oct 2023 | 0d | filed |
| MGT-7 | FY2023-24 | 20 Nov 2023 | 29 Nov 2023 | 0d | filed |
| AOC-4 | FY2022-23 | 30 Oct 2022 | 30 Oct 2022 | 0d | filed |
| MGT-7 | FY2022-23 | 26 Nov 2022 | 29 Nov 2022 | 0d | filed |
Full MCA filing history for Aurobindo Pharma Ltd.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Charges
Locked| Charge ID | Holder | Amount | Created | Status |
|---|---|---|---|---|
| 631467094 | Axis Bank Ltd(Bank) | ₹2.45 Cr | 27 Jan 2022 | Satisfied |
| 156121876 | State Bank of India(Bank) | ₹15.22 Cr | 27 Jan 2021 | Satisfied |
| 793338871 | ICICI Bank Ltd(Bank) | ₹15.56 Cr | 12 Mar 2020 | Open |
| 782087962 | Kotak Mahindra Bank Ltd(Bank) | ₹20.83 Cr | 12 Mar 2019 | Open |
| 536616505 | ICICI Bank Ltd(Bank) | ₹4.08 Cr | 12 Mar 2023 | Open |
| 352999237 | Axis Bank Ltd(Bank) | ₹9.28 Cr | 27 Jan 2021 | Open |
Charge IDs, lenders & amounts for Aurobindo Pharma Ltd.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Financial Performance
MCA| FY | Revenue | PAT | Net Worth | Total Assets | Employees |
|---|---|---|---|---|---|
| 2020-21 | — | ||||
| 2015-16 | — |
Detailed Financials
2 FYs| Line item | 2020-21 | 2015-16 |
|---|---|---|
| Income statement | ||
| Revenue from operations | ||
| Other income | ||
| Total income | ||
| Total expenses | ||
| Profit before tax | ||
| Profit / (Loss) after tax | ||
| Balance sheet | ||
| Equity / Net worth | ||
| Borrowings | ||
| Current liabilities | ||
| Total liabilities | ||
| Current assets | ||
| Cash & equivalents | ||
| Total assets | ||
| Employees | — | — |
Cash-flow statement renders when the AOC-4 XBRL Cash Flow context is parsed during the extract phase.
Compounded Annual Growth Rate
| Metric | Latest value | 1Y CAGR | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|
| Revenue2020-21 | +73.0% | — | — | |
| Profit after Tax2020-21 | +97.0% | — | — | |
| Net Worth2020-21 | +286.0% | — | — |
Financial Ratios
| FY | Revenue | PAT | PAT margin | Rev growth | ROE | ROA | D/E | Rev/emp |
|---|---|---|---|---|---|---|---|---|
| 2015-16 | +17.32% | — | +23.78% | +13.57% | — | |||
| 2020-21 | +19.67% | +69.25% | +19.55% | +13.42% | 0.46 |
Cap Table & Shareholding
Locked| Category | Shareholders | Shares held | % |
|---|---|---|---|
| Promoters | 1 | 1,86,84,891 | 70.81% |
| Institutional Investors | 3 | 14,95,288 | 5.67% |
| Public & Others | 24 | 62,07,280 | 23.52% |
Promoter, institutional & public holding for Aurobindo Pharma Ltd.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Peer Benchmark
4 peersEvents & timeline
3External data sources
7 plannedGSTIN Registrations
Per-state GSTINs + GSTR-1/3B filing cadence + turnover bracket. PAN-keyed scrape.
MSME Payment Delays
Half-yearly disclosure of payments delayed beyond 45 days to MSME suppliers.
Related Party Transactions
Counterparty, nature, transaction value. Inter-company loans, sales, royalty.
Credit Ratings
Long-term + short-term ratings, with rationale on rating actions.
Trademarks
Applied, registered, opposed. Class numbers + status.
Patents
Applications and grants. Inventor names + filing dates.
Legal Cases
Ongoing + past litigations the entity is party to.
Each source is wired as a separate ingestion adapter behind the scraper. Live status flips per CIN as records land.